Your body accumulates broken cells. They stop dividing but refuse to die. Researchers call them senescent cells. The longevity community calls them zombie cells. Whatever the name, they sit in your tissues, leak inflammatory signals, and accelerate aging in the organs around them. Clearing them — a process closely tied to autophagy — is the premise behind an entire class of compounds called senolytics.
Fisetin is the one that caught everyone’s attention.
The Mouse Data That Started It#
In 2018, researchers at the Mayo Clinic and University of Minnesota tested fisetin alongside 9 other flavonoids for senolytic activity. Fisetin came out on top. When administered to aged mice (the equivalent of roughly 75 human years), it extended median lifespan by approximately 10% and reduced senescence markers across multiple tissues. The treated mice had lower inflammatory cytokines, better organ function, and fewer senescent cells in kidney, liver, and fat tissue.
That study, published in EBioMedicine, is probably the single most-cited paper in the consumer senolytic space. It is a strong result. It is also a mouse study.
The Human Data — Honest Version#
The longevity community moved fast. Supplement companies moved faster. But the human evidence has been slower and less dramatic.
A pilot study published in 2024 tested fisetin in 10 healthy adults over the age of 50. The results were genuinely mixed. Four participants showed a reduction in biological age markers. Five showed an increase in biological age. One showed no change. That is a 40% response rate in a 10-person trial with no control group.
This is not a failure. It is early-stage research doing exactly what early-stage research does — generating data to inform the next trial. But it is also not the confirmation that the supplement industry has been selling for the past six years. If you bought fisetin capsules based on a blog post that cited only the mouse study, this is the part they left out.
The Mechanism#
Fisetin clears senescent cells through a specific molecular pathway. It inhibits the Pi3k-Akt signaling cascade, which downregulates the anti-apoptotic proteins Bcl-2 and Bcl-xl. In plain language: senescent cells survive by blocking their own death signals. Fisetin removes that block.
This mechanism is well-characterized in cell culture and animal models. The question is whether oral dosing in humans achieves tissue concentrations sufficient to trigger the same effect. Fisetin has low bioavailability. Most of what you swallow gets metabolized before it reaches the cells you are trying to clear.
The Animal Data Keeps Coming#
While the human evidence stalls at pilot-study size, the preclinical work continues to look promising. A 2025 study found that intermittent fisetin administration improved physical function and decreased cellular senescence in skeletal muscle in aged mice. The intermittent dosing schedule matters — it suggests that senolytic benefit may come from periodic clearing rather than daily supplementation.
This aligns with the broader senolytic hypothesis: you do not need to take the compound every day. You hit the senescent cells with a short, high-dose course, clear them, then wait for new ones to accumulate before repeating. It is a different model from the daily-supplement approach most consumers default to.
What Is Actually In the Pipeline#
The most serious clinical application of fisetin right now is not in longevity. A multi-center randomized controlled trial is underway testing fisetin in 220 patients with sepsis. Sepsis drives rapid cellular senescence, and the inflammatory burden from senescent cells worsens outcomes. This trial, if completed, will produce the largest human dataset on fisetin’s senolytic effects to date.
There are also ongoing trials for osteoarthritis, chronic kidney disease, and frailty in older adults. The results from these will tell us far more than any 10-person pilot. Until they report, the honest answer to “does fisetin work in humans” is: we do not know yet.
The Conservative Bet#
You do not need a capsule to get fisetin. Strawberries contain the highest fisetin concentration of any common food, at roughly 160 micrograms per gram. That is orders of magnitude below the supplemental doses used in trials (typically 20 mg/kg body weight), but it comes packaged with fiber, vitamin C, anthocyanins, and none of the bioavailability concerns of isolated supplements.
The Chobani Fisetin Yogurt Bowl on this site pairs a full cup of strawberries with high-protein Greek yogurt. It delivers a measurable dietary dose of fisetin alongside 30g+ protein. It is not a senolytic intervention. It is breakfast that happens to contain the compound everyone is talking about, in the form your body evolved to process.
Where This Leaves You#
The fisetin story is a good test case for how to think about longevity research in general. The mouse data is real and compelling. The mechanism is well-understood. The human data is early, small, and mixed. The clinical pipeline is active but years from reporting.
If you are taking fisetin supplements based on the 2018 mouse study, you are running an experiment on yourself with incomplete information. That is your choice to make. But you should make it with full knowledge of what the human data actually shows — not the curated version from the company selling you the capsules.
The conservative position: eat the strawberries. Fix the inputs. Track the trials. Read the papers when they publish. Do not pretend the science is settled when the largest human dataset is 10 people.
That is where the research stands. Not exciting. Not hopeless. Just early.
New and seasonal recipes, and what's working. Once a month. No ads, no fluff.